3 Top-Rated Dividend Stocks To Buy In Q2 2021

VZ currently has a dividend yield of 4.4%, which is much higher than its industry average. The company has an overall grade of B, which translates into a Buy rating in our POWR Ratings system. The company has a Stability Grade of B, which means its growth figures and price performance are stable. VZ also has a Quality Grade of B due to the strength in its balance sheet.

The company has a current ratio of 1.4, which indicates it has more than enough liquidity to handle short-term obligations. We also rate VZ based on Growth, Value, Momentum, and Sentiment. You can find those grades here. VZ is ranked #1 in the Telecom – Domestic industry. You can find other top stocks in this industry by clicking here.  

Pfizer, Inc. (PFE

PFE is one of the world’s largest pharmaceutical firms, with annual sales of close to $50 billion. The company is also an industry leader in terms of money spent on research and development, with close to $8 billion spent annually. While PFE has historically sold various types of healthcare products and chemicals, prescription drugs and vaccines now account for most sales.

The company markets a wide range of drugs and vaccines and boasts a sustainable pipeline of multiple late-stage programs that should drive future growth. The company’s massive size offers a significant competitive advantage in the development of new drugs. PFE is launching several potential blockbusters drugs in the areas of cancer, heart disease, and immunology.

Its broad portfolio of patent-protected drugs and expected COVID-19 vaccine sales should lead to a strong showing this year. PFE has a dividend yield of 4.2%, which has grown an average of 5.4% over the past five years. The company has an overall grade of B, which is a Buy rating in our POWR ratings service. PFE has a Value Grade of B, which isn’t surprising with a forward P/E of 11.47.

PFE also has a healthy balance sheet, which has led to a Quality Grade of B. As of the end of last year, the company had $12.2 billion in cash, compared with $2.7 billion in short-term debt. To access the rest of PFE’s grades (Growth, Momentum, Stability, and Sentiment), click here. PFE is ranked #25 in the Medical – Pharmaceuticals industry. For other top stocks in this industry, click here.  

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.